LBT999
Traumatic Brain Injury
Institut National de la Santé Et de la Recherche Médicale, FranceSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
92 Active assets in the Traumatic Brain Injury cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MELATONIN Children's National Research Institute | Phase 4 | BBB |
Valproic Acid Northwestern University | Phase 4 | BBB |
PROPRANOLOL Tanta University | Phase 4 | BBB |
NEPENTHE Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 4 | BB |
Amantadine SHINKEI Therapeutics, Inc | Phase 4 | BB |
View all 50 →
Same molecule, other indications
LBT999 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →